Lipocine Company Profile (NASDAQ:LPCN)

About Lipocine

Lipocine logoLipocine Inc. is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for bioavailable drugs. Its lead product candidate, LPCN 1021, is an oral testosterone replacement therapy (TRT), designed for twice-a-day dosing and is in Phase III testing. The Company's additional pipeline candidates include LPCN 1111, an oral testosterone therapy product targeted for once daily dosing, which is in Phase II testing, and LPCN 1107, an oral therapy for the prevention of preterm birth, which is in Phase I testing. These products are based on its Lip'ral promicellar drug delivery technology platform. Lip'ral promicellar technology is a technology based on lipidic compositions, which form an optimal dispersed phase in the gastrointestinal environment for improved absorption of insoluble drugs.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: LPCN
  • CUSIP:
Key Metrics:
  • Previous Close: $3.91
  • 50 Day Moving Average: $3.62
  • 200 Day Moving Average: $3.71
  • 52-Week Range: $2.51 - $12.66
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.12
  • P/E Growth: 0.00
  • Market Cap: $71.40M
  • Outstanding Shares: 18,260,000
  • Beta: 1.88
Profitability:
  • Return on Equity: -59.35%
  • Return on Assets: -55.10%
Debt:
  • Current Ratio: 18.73%
  • Quick Ratio: 18.73%
Additional Links:
Companies Related to Lipocine:

Analyst Ratings

Consensus Ratings for Lipocine (NASDAQ:LPCN) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $23.33 (496.76% upside)

Analysts' Ratings History for Lipocine (NASDAQ:LPCN)
Show:
DateFirmActionRatingPrice TargetDetails
1/18/2017HC WainwrightReiterated RatingBuyView Rating Details
12/20/2016Canaccord GenuitySet Price TargetBuy$15.00View Rating Details
12/6/2016Roth CapitalSet Price TargetBuy$30.00View Rating Details
7/17/2015Evercore ISIInitiated CoverageBuy$18.00View Rating Details
7/16/2015Evercore Partners Inc.Initiated CoverageBuy$18.00View Rating Details
(Data available from 2/23/2015 forward)

Earnings

Earnings History for Lipocine (NASDAQ:LPCN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/8/2017        
5/9/2016Q1($0.33)($0.38)ViewN/AView Earnings Details
11/12/2015Q3($0.35)($0.35)ViewN/AView Earnings Details
8/11/2015($0.20)($0.26)ViewN/AView Earnings Details
5/7/2015($0.35)($0.23)ViewN/AView Earnings Details
3/11/2015($0.35)($0.32)ViewN/AView Earnings Details
11/10/2014($0.58)($0.32)ViewN/AView Earnings Details
8/13/2014($0.42)($0.55)ViewN/AView Earnings Details
5/14/2014($0.35)($0.41)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Lipocine (NASDAQ:LPCN)
Current Year EPS Consensus Estimate: $-1.10 EPS
Next Year EPS Consensus Estimate: $-0.95 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.34)($0.19)($0.27)
Q2 20162($0.38)($0.34)($0.36)
Q3 20162($0.32)($0.29)($0.31)
Q4 20162($0.22)($0.18)($0.20)
Q1 20171($0.21)($0.21)($0.21)
Q2 20171($0.20)($0.20)($0.20)
Q3 20171($0.12)($0.12)($0.12)
Q4 20171($0.15)($0.15)($0.15)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Lipocine (NASDAQ:LPCN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Lipocine (NASDAQ:LPCN)
Insider Ownership Percentage: 10.00%
Institutional Ownership Percentage: 45.02%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/30/2015John W HiguchiDirectorBuy5,000$12.68$63,400.00View SEC Filing  
9/30/2015Mahesh V. PatelCEOBuy4,000$11.84$47,360.00View SEC Filing  
11/25/2014Mahesh V PatelCEOBuy2,000$5.10$10,200.00View SEC Filing  
11/24/2014Mahesh V PatelCEOBuy2,000$5.45$10,900.00View SEC Filing  
11/19/2014Richard Dana OnoDirectorBuy4,000$5.14$20,560.00View SEC Filing  
11/14/2014Mahesh V PatelCEOBuy2,000$5.06$10,120.00View SEC Filing  
11/13/2014Mahesh V PatelCEOBuy2,000$5.05$10,100.00View SEC Filing  
11/13/2014Stephen A HillDirectorBuy4,000$4.95$19,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Lipocine (NASDAQ:LPCN)
DateHeadline
News IconEPS Of Lipocine Inc. (NASDAQ:LPCN) At $-0.23 | Stock Observer - Stock Observer (NASDAQ:LPCN)
www.thestockobserver.com - February 23 at 6:20 PM
News IconEquity Focus: Looking at Shares of Lipocine Inc (LPCN) - Rives Journal (NASDAQ:LPCN)
rivesjournal.com - February 23 at 6:13 AM
News IconBrokerage Firm Analysts Have Spoken and the Consensus is in on Lipocine Inc. (NASDAQ:LPCN) - Rockville Register (NASDAQ:LPCN)
rockvilleregister.com - February 20 at 5:44 PM
News IconStock Review: Level Check for Lipocine Inc. (NASDAQ:LPCN) - Piedmont Register (NASDAQ:LPCN)
piedmontregister.com - February 17 at 1:25 PM
finance.yahoo.com logoLipocine Announces the Promotion of Gregory Bass to Chief Commercial Officer - Yahoo Finance (NASDAQ:LPCN)
finance.yahoo.com - February 17 at 1:25 PM
4-traders.com logoLIPOCINE INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) (NASDAQ:LPCN)
www.4-traders.com - February 16 at 5:55 PM
biz.yahoo.com logoLIPOCINE INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:LPCN)
biz.yahoo.com - February 8 at 7:07 PM
News IconTechnical Indicator Review on Shares of Lipocine Inc (LPCN) - Sherwood Daily (NASDAQ:LPCN)
sherwooddaily.com - February 3 at 7:02 PM
News IconInside Track: Trading Focus on Shares of Lipocine Inc (LPCN) - Sherwood Daily (NASDAQ:LPCN)
sherwooddaily.com - February 1 at 7:09 PM
News IconAre Analysts Forecasting a Near-Term Upswing For Lipocine Inc. (NASDAQ:LPCN)? - Wall Street Beacon (NASDAQ:LPCN)
wsbeacon.com - February 1 at 7:09 PM
streetinsider.com logoForm 4 Lipocine Inc. For: Jan 26 Filed by: BROWN MORGAN R (NASDAQ:LPCN)
www.streetinsider.com - January 31 at 5:06 AM
News IconCalibrating the Trade: Watching Technicals on Shares of Lipocine Inc (LPCN) - Sherwood Daily (NASDAQ:LPCN)
sherwooddaily.com - January 31 at 12:05 AM
News IconQuick Review on Trend Indicator Levels: Lipocine Inc (LPCN) - Sherwood Daily (NASDAQ:LPCN)
sherwooddaily.com - January 27 at 11:06 PM
News IconEarnings in Full Force, Analysts Take Aim at Lipocine Inc. (NASDAQ:LPCN) - Wall Street Beacon (NASDAQ:LPCN)
wsbeacon.com - January 27 at 11:06 PM
News IconLipocine Inc LPCN Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:LPCN)
www.bioportfolio.com - January 26 at 8:10 PM
News IconLipocine Inc (LPCN) Valuation According To Analysts - UK Market ... - UK Market News (NASDAQ:LPCN)
www.ukmarketnews.co.uk - January 26 at 5:48 AM
News IconInvesting Focus: Indicators in View on Shares of Lipocine Inc (LPCN) - Sherwood Daily (NASDAQ:LPCN)
sherwooddaily.com - January 23 at 6:37 PM
News IconShooting From the Hip, Stock Reaches Most Volatile List: Lipocine Inc. (NASDAQ:LPCN) - Wall Street Beacon (NASDAQ:LPCN)
wsbeacon.com - January 18 at 11:53 PM
News IconPumping the Brakes as Stock Dragged Lower Mid-Session: Lipocine Inc. (NASDAQ:LPCN) - Wall Street Beacon (NASDAQ:LPCN)
wsbeacon.com - January 18 at 6:51 PM
News IconGearing Up For a Bull Run? Analysts Weigh in on Lipocine Inc. (NASDAQ:LPCN) - Wall Street Beacon (NASDAQ:LPCN)
wsbeacon.com - January 18 at 6:51 PM
4-traders.com logoLipocine : Initiates a Dosing Flexibility Study for LPCN 1021, Its Oral Testosterone Replacement Product Candidate (NASDAQ:LPCN)
www.4-traders.com - January 17 at 6:42 PM
News IconLipocine Inc (LPCN) Analyst Coverage - NewsDen (NASDAQ:LPCN)
newsden.net - January 17 at 11:59 AM
News IconAre There Catalysts to Propel This Stock Forward: Lipocine Inc. (NASDAQ:LPCN) - Prospect Journal (NASDAQ:LPCN)
prospectjournal.com - January 16 at 6:57 PM
News IconEPS Of Lipocine Inc. (NASDAQ:LPCN) At $-0.31 - Stock Observer (NASDAQ:LPCN)
www.thestockobserver.com - January 12 at 11:54 PM
News IconWill The Needle Move For Lipocine Inc. (NASDAQ:LPCN) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:LPCN)
wsbeacon.com - January 12 at 11:54 PM
nasdaq.com logoLipocine Receives FDA Guidance on the Phase 3 Program for LPCN 1107, an Oral Alternative for the Prevention of ... - Nasdaq (NASDAQ:LPCN)
www.nasdaq.com - January 11 at 5:18 AM
News IconNews Impact Score Of Lipocine Inc. (NASDAQ:LPCN) Set At 0 - Stock Observer (NASDAQ:LPCN)
www.thestockobserver.com - January 11 at 5:18 AM
News IconCommit To Buy Lipocine At $2.50, Earn 10% Annualized Using Options (NASDAQ:LPCN)
www.stockoptionschannel.com - January 10 at 7:14 PM
streetinsider.com logoLipocine (LPCN) Receives Additional FDA Guidance on LPCN 1107 Pivotal Phase 3 Study Design (NASDAQ:LPCN)
www.streetinsider.com - January 9 at 7:06 PM
us.rd.yahoo.com logoLipocine Receives FDA Guidance on the Phase 3 Program for LPCN 1107, an Oral Alternative for the Prevention of Preterm Birth (NASDAQ:LPCN)
us.rd.yahoo.com - January 9 at 7:06 PM
reuters.com logoBRIEF-Lipocine Inc plans to initiate a dosing flexibility study (NASDAQ:LPCN)
www.reuters.com - January 6 at 6:59 PM
finance.yahoo.com logoLPCN: Early Start to Tlando Validation Trial (NASDAQ:LPCN)
finance.yahoo.com - January 6 at 6:59 PM
streetinsider.com logoForm 8-K Lipocine Inc. For: Jan 05 - StreetInsider.com - StreetInsider.com (NASDAQ:LPCN)
www.streetinsider.com - January 6 at 5:48 AM
streetinsider.com logoLipocine (LPCN) to Initiates LPCN 1021 Dosing Flexibility Study (NASDAQ:LPCN)
www.streetinsider.com - January 5 at 7:45 PM
us.rd.yahoo.com logoLipocine Initiates a Dosing Flexibility Study for LPCN 1021, Its Oral Testosterone Replacement Product Candidate (NASDAQ:LPCN)
us.rd.yahoo.com - January 5 at 7:45 PM
us.rd.yahoo.com logo8:05 am Lipocine to initiate a dosing flexibility study in addition to its previously announced dosing validation study for LPCN 1021; expects top-line results in 2Q17 (NASDAQ:LPCN)
us.rd.yahoo.com - January 5 at 7:45 PM
News IconLipocine Inc. (NASDAQ:LPCN) News Impact Score At 0 - Stock Observer (NASDAQ:LPCN)
www.thestockobserver.com - January 3 at 10:12 PM
News IconLipocine Inc. (NASDAQ:LPCN) EPS At $-0.31 - Stock Observer (NASDAQ:LPCN)
www.thestockobserver.com - December 29 at 11:24 PM
News IconIndicator Level Summary for Lipocine Inc (LPCN) - Yankee Analysts (NASDAQ:LPCN)
yankeeanalysts.com - December 16 at 6:56 PM
News IconEPS Of Lipocine Inc. (NASDAQ:LPCN) Set At $-0.31 - Stock Observer (NASDAQ:LPCN)
www.thestockobserver.com - December 16 at 12:02 AM
News IconInvestors are Watching Technical Levels on Shares of Lipocine Inc (LPCN) - Yankee Analysts (NASDAQ:LPCN)
yankeeanalysts.com - December 16 at 12:02 AM
News IconUpside Alert: Delving into Shares of Lipocine Inc. (NASDAQ:LPCN) - Prospect Journal (NASDAQ:LPCN)
prospectjournal.com - December 13 at 11:48 PM
News IconNews Impact Score Of Lipocine Inc. (NASDAQ:LPCN) At 0 - Stock Observer (NASDAQ:LPCN)
www.thestockobserver.com - December 13 at 11:48 PM
News IconTrading Insight: Taking a Look at Levels for Lipocine Inc (LPCN) - Yankee Analysts (NASDAQ:LPCN)
yankeeanalysts.com - December 13 at 11:48 PM
News IconNews Impact Score Of Lipocine Inc. (NASDAQ:LPCN) At 50 - Stock Observer (NASDAQ:LPCN)
www.thestockobserver.com - December 7 at 10:04 AM
marketexclusive.com logoLIPOCINE INC. (NASDAQ:LPCN) Files An 8-K Regulation FD Disclosure - Market Exclusive (NASDAQ:LPCN)
marketexclusive.com - December 7 at 10:04 AM
News IconRelative Strength Index Review on Shares of Lipocine Inc (LPCN) - Yankee Analysts (NASDAQ:LPCN)
yankeeanalysts.com - December 7 at 10:04 AM
capitalcube.com logoLipocine, Inc. :LPCN-US: Earnings Analysis: Q3, 2016 By the Numbers : December 6, 2016 (NASDAQ:LPCN)
www.capitalcube.com - December 6 at 6:10 PM
rttnews.com logoCERC's Woes Continue, TXMD Replenished By Trial Data, NDRM Abuzz, SRNE On Watch (NASDAQ:LPCN)
www.rttnews.com - December 6 at 10:05 AM
biz.yahoo.com logoLIPOCINE INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:LPCN)
us.rd.yahoo.com - December 6 at 10:05 AM

Social

What is Lipocine's stock symbol?

Lipocine trades on the NASDAQ under the ticker symbol "LPCN."

Where is Lipocine's stock going? Where will Lipocine's stock price be in 2017?

3 analysts have issued twelve-month target prices for Lipocine's shares. Their predictions range from $15.00 to $30.00. On average, they expect Lipocine's share price to reach $23.33 in the next year.

When will Lipocine announce their earnings?

Lipocine is scheduled to release their next quarterly earnings announcement on Wednesday, March, 8th 2017.

Who owns Lipocine stock?

Lipocine's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Royce & Associates LP (6.46%), Dimensional Fund Advisors LP (1.42%), State Street Corp (1.29%) and Federated Investors Inc. PA (0.45%). Company insiders that own Lipocine stock include John W Higuchi and Mahesh V Patel.

Who sold Lipocine stock? Who is selling Lipocine stock?

Lipocine's stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP.

Who bought Lipocine stock? Who is buying Lipocine stock?

Lipocine's stock was acquired by a variety of institutional investors in the last quarter, including Royce & Associates LP, State Street Corp and Federated Investors Inc. PA. Company insiders that have bought Lipocine stock in the last two years include John W Higuchi and Mahesh V Patel.

How do I buy Lipocine stock?

Shares of Lipocine can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Lipocine stock cost?

One share of Lipocine stock can currently be purchased for approximately $3.91.

Lipocine (NASDAQ:LPCN) Chart for Thursday, February, 23, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Lipocine (NASDAQ:LPCN)

Earnings History Chart

Earnings by Quarter for Lipocine (NASDAQ:LPCN)

Dividend History Chart

Dividend Payments by Quarter for Lipocine (NASDAQ:LPCN)

Last Updated on 2/23/2017 by MarketBeat.com Staff